These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 6990991)
21. [Therapy of hyperlipoproteinemia type IIa, IIb and IV with Etofibrate retard]. Schwartzkopff W; Schilling A; Calder D Med Welt; 1980 Apr; 31(14):515-20. PubMed ID: 7374415 [No Abstract] [Full Text] [Related]
22. Clinical study of niceritrol on serum lipids in the treatment of hyperlipidemia. Kibata M; Ishida M; Asano K; Uehara H; Saito K; Fuchimoto T; Ugaki K; Murakami H; Matoba K; Kotakemori Y; Shirai K; Yoshioka H; Nanba M; Yasuda M; Ishizaki M; Kitagawa N; Ikejiri K; Inohara R; Lee BJ; Saino S; Sakado J; Matuzaka H; Numata K; Mandai M; Miyake K; Nakamura K Atherosclerosis; 1980 Nov; 37(3):333-42. PubMed ID: 7458980 [TBL] [Abstract][Full Text] [Related]
23. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975 [TBL] [Abstract][Full Text] [Related]
24. Lack of effect of ascorbic acid on serum lipoprotein concentrations in patients with hypertriglyceridaemia. Wahlberg G; Walldius G Atherosclerosis; 1982 Jun; 43(2-3):283-8. PubMed ID: 7115465 [TBL] [Abstract][Full Text] [Related]
25. Effects of probucol on plasma cholesterol, high and low density lipoprotein cholesterol, and apolipoproteins A1 and A2 in adults with primary familial hypercholesterolemia. Mellies MJ; Gartside PS; Glatfelter L; Vink P; Guy G; Schonfeld G; Glueck CJ Metabolism; 1980 Oct; 29(10):956-64. PubMed ID: 6999291 [No Abstract] [Full Text] [Related]
26. [Evaluation of the effectiveness of gemfibrozil in primary dyslipoproteinemias. II. Relation between the results of treatment and type of dyslipoproteinemia]. Sznajd J; Malczewska-Malec M; Idzior-Waluś B; Iwanejko J; Nowacki G Przegl Lek; 1987; 44(12):837-43. PubMed ID: 3330253 [No Abstract] [Full Text] [Related]
27. On the rise in low density and high density lipoproteins in response to the treatment of hypertriglyceridaemias in type IV and type V hyperlipoproteinaemias. Carlson LA; Olsson G; Ballantyne D Atherosclerosis; 1977 Apr; 26(4):603-9. PubMed ID: 193526 [TBL] [Abstract][Full Text] [Related]
28. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate. Rössner S; Orö L Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166 [TBL] [Abstract][Full Text] [Related]
29. Effects of clofibrate, nicotinic acid and diet on the properties of the plasma lipoproteins in a subject with type III hyperlipoproteinemia. Patsch JR; Yeshurun D; Jackson RL; Gotto AM Am J Med; 1977 Dec; 63(6):1001-9. PubMed ID: 204188 [No Abstract] [Full Text] [Related]
31. [Effect of lipanthyl on parameters of lipid metabolism in patients with primary hyperlipoproteinemia]. Sznajd J; Magdoń M; Idzior B; Konarska R; Malczewska M; Czarnecka H Przegl Lek; 1984; 41(2):217-21. PubMed ID: 6377392 [No Abstract] [Full Text] [Related]
32. The effect of D-thyroxine on lipoprotein lipids and apolipoproteins in primary type IIa hyperlipoproteinemia. Schwandt P; Weisweiler P Atherosclerosis; 1980 Mar; 35(3):301-6. PubMed ID: 6987993 [TBL] [Abstract][Full Text] [Related]
33. Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism. Shepherd J; Packard CJ; Patsch JR; Gotto AM; Taunton OD J Clin Invest; 1979 May; 63(5):858-67. PubMed ID: 221531 [TBL] [Abstract][Full Text] [Related]
34. Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients. Weisweiler P; Schwandt P Atherosclerosis; 1981 Apr; 39(1):45-9. PubMed ID: 7247989 [TBL] [Abstract][Full Text] [Related]
35. [Familial hyperlipoproteinemia type III]. Patsch JR; Patsch W; Sailer S; Braunsteiner H Dtsch Med Wochenschr; 1976 Oct; 101(44):1612-9. PubMed ID: 185039 [No Abstract] [Full Text] [Related]
36. Normalization of triglycerides in type IV hyperlipoproteinemia fails to correct low levels of high-density-lipoprotein cholesterol. Witztum JL; Dillingham MA; Giese W; Bateman J; Diekman C; Blaufuss EK; Weidman S; Schonfeld G N Engl J Med; 1980 Oct; 303(16):907-14. PubMed ID: 7412822 [TBL] [Abstract][Full Text] [Related]
37. The hypolipidemic action of probucol: a study of its effects on high and low density lipoproteins. Atmeh RF; Stewart JM; Boag DE; Packard CJ; Lorimer AR; Shepherd J J Lipid Res; 1983 May; 24(5):588-95. PubMed ID: 6875383 [TBL] [Abstract][Full Text] [Related]
38. Pseudohomozygous type II hyperlipoproteinemia. Morganroth J; Levy RI; McMahon AE; Gotto AM J Pediatr; 1974 Nov; 85(5):639-43. PubMed ID: 4370845 [No Abstract] [Full Text] [Related]
39. [Effect of beta-pyridylcarbinol on lipids and lipoprotein in primary type IIa hyperlipoproteinemia]. Hutt V; Wechsler JG; Klör HU; Ditschuneit H Arzneimittelforschung; 1983; 33(12):1682-4. PubMed ID: 6686774 [TBL] [Abstract][Full Text] [Related]
40. Type III hyperlipoproteinemia: rise in high-density lipoprotein levels in response to therapy. Falko JM; Witztum JL; Schonfeld G; Weidman SW; Kolar JB Am J Med; 1979 Feb; 66(2):303-10. PubMed ID: 218451 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]